This Week in Biotech: NW Bio Soars While Geron Goes Geronimo
Two early-stage study results, a rare hospital exemption approval in Germany, and a devastating full clinical hold for one biotech are among this week's top biotech stories.
Why Geron, Express, and Herbalife Tumbled Today
The S&P 500 managed to end a two-day losing streak Wednesday with very modest gains, but many stocks couldn't recover from severe losses. Find out what made these three stocks drop today.
Geron Is Dead in the Water, but Not Sunk Yet
When people consider you an oncology company, losing your only oncology drug can sting.
Why Geron Corporation Shares Were Mauled
Geron shares are turned upside down after updating the status of its imetelstat development program. Is this dip a buying opportunity or all the more reason to hit the exit?